As Rare Disease Day is commemorated on 28 February, experts discuss the barriers to gene therapy access for some rare ...

The FDA has accepted Sobi’s sBLA for Gamifant for haemophagocytic lymphohistiocytosis (HLH)/MAS associated with Still’s ...

The MSSG solidarity mechanism enables medicine sharing between EU states, with companies now required to report on drug ...

The FDA has granted fast track designation to Pyxis oncology’s PYX-201 for the treatment of adults with R/M HNSCC.

New EU Clinical Trial Regulations simplify international trials while offering the means to counter drug shortages for trials ...

Medigene and EpimAb Biotherapeutics have signed a co-development agreement involving T cell receptor (TCR)-guided T cell ...

Last month, the NICE endorsed Casgevy for use in the NHS under a managed access scheme to treat sickle cell disease.

Vietnam is aiming to attract overseas investment to encourage domestic drug development through the amended 2016 Law on ...

Eli Lilly has announced plans to expand its domestic medicine production in the US with four new pharmaceutical manufacturing ...

Deal numbers dropped in January this year compared to last, with outbound deals trumping inbound transactions.

A survey has shown that pharma companies have low confidence their rare disease medicines can launch in the UK.

Zevra has sold its US Food and Drug Administration (FDA) priority review voucher (PRV) for $150m to an undisclosed party.